Alligator Bioscience AB (ATORX) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Net Sales has grown by an annual rate of 57.57% and Operating profit at 1.18% over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -108.20

Flat results in Jun 25

Risky -

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

SEK 48 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

1.69

Return on Equity

1,068.47%

Price to Book

-5.19

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-64.02%

6 Months

-63.13%

1 Year

-92.92%

2 Years

-96.39%

3 Years

-98.34%

4 Years

-98.75%

5 Years

-99.53%

Alligator Bioscience AB for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

57.57%

EBIT Growth (5y)

1.18%

EBIT to Interest (avg)

-108.20

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.20

Sales to Capital Employed (avg)

-0.40

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-5.39

EV to EBIT

-0.79

EV to EBITDA

-1.01

EV to Capital Employed

-2.76

EV to Sales

3.77

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bullish

Bearish

OBV

Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs -100.00% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 79.52% vs 85.02% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-34.60",
          "val2": "-47.70",
          "chgp": "27.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "17.50",
          "val2": "13.80",
          "chgp": "26.81%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "12.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.70",
          "val2": "-8.30",
          "chgp": "79.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -0.52% vs 62.75% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 5.91% vs -28.54% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "57.80",
          "val2": "58.10",
          "chgp": "-0.52%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-182.40",
          "val2": "-242.30",
          "chgp": "24.72%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "19.70",
          "val2": "0.50",
          "chgp": "3,840.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-233.90",
          "val2": "-248.60",
          "chgp": "5.91%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-4,000.30%",
          "val2": "-4,350.20%",
          "chgp": "34.99%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-34.60

-47.70

27.46%

Interest

17.50

13.80

26.81%

Exceptional Items

12.20

0.00

Consolidate Net Profit

-1.70

-8.30

79.52%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs -100.00% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 79.52% vs 85.02% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

57.80

58.10

-0.52%

Operating Profit (PBDIT) excl Other Income

-182.40

-242.30

24.72%

Interest

19.70

0.50

3,840.00%

Exceptional Items

0.00

Consolidate Net Profit

-233.90

-248.60

5.91%

Operating Profit Margin (Excl OI)

-4,000.30%

-4,350.20%

34.99%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -0.52% vs 62.75% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 5.91% vs -28.54% in Dec 2023

All Annual Results

Company CV

About Alligator Bioscience AB

Alligator Bioscience AB

Pharmaceuticals & Biotechnology

Alligator Bioscience AB is a Sweden-based company that is engaged in development of immunotherapies for the treatment of cancer. The Company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. In the discovery of those drugs, the Company uses its technology platforms ALLIGATOR-GOLD and FIND. ALLIGATOR-GOLD is a library containing human antibodies. FIND (which stands for Fragment Induced Diversity) is an antibody optimization technology. In its pipeline, the Company has thee projects: ADC-1013 (antibody), ATOR-1015 (bispecific immune activating antibody) and ATOR-1016 (bispecific agonistic antibody), which are in research/preclinical stage.

Company Coordinates

Company Details

Scheelevagen 2 Byggnad 401 , LUND None : 223 63

Tel: 46 46 2864280

https://alligatorbioscience.se/

Registrar Details